Top Growth Investments

Brain Scientific is a top growth
pick for 2021 and beyond.
OTC: BRSF

Stay updated on company news and announcements

Why Invest in Brain Scientific

Revolutionizing the EEG market, making neurological care affordable & accessible to all

Major disruptor with a cheaper, simpler & more practical alternative to conventional technology

Owner of 2 patented, FDA approved products for wirelessly connected EEG test technologies

Positioned for explosive growth due to a severe access shortages (70% of hospitals lack EEGs)

Developing long-term monitoring capabilities using the Nobel Prize graphene materials

Massive market of over 100 million patients in the USA alone

Closely aligned with telemedicine & Med-Tech sectors (continuous Quarter over Quarter growth)

Highly experienced executive team in all relevant fields with proven track records

Global Market Potential

Massive Patient Base

EEG tests are vastly undersupplied throughout the US, and globally it’s worse. This is due to a lack of readily available hardware, which is already operated on dated technology and equipment. The shortage is exacerbated by a lack of trained and qualified medical staff to administer and then interpret the results of the EEG tests.

These patients include people of all ages: TBIs and head traumas arriving in ICUs and EDs as well as suffers of epilepsy, Alzheimer’s, dementia, strokes, seizures, sleeping disorders, migraines, and encephalitis.

5 million

ICU and ED patients are candidates for EEGs each year, yet only ~25% of these receive the test because departments do not have the available technology or specialists

5.8 million

Alzheimer’s suffers in the USA - 1 person diagnosed with it every 65 seconds in the US

1.6 - 3.8 million

Concussion occur each year in the USA

3.4 million

Suffers of epilepsy nationwide

50-70 million

US adults have a sleeping disorder

30 million

Migraine suffers in the USA

1 person per min.

Is affected by encephalitis in the US

16.2 million

Suffers of depression - Most common in those aged 18 - 25

800,000 per year

In the USA someone has a stroke every 40 seconds

Sources: World Health Organization & Johns Hopkins

Brain Scientific is a great opportunity for seasoned industry veterans as well as first time investors.

1.25 - 5 million

ICU and ER patients

9.2 million

Epilepsy and Alzheimer's sufferers

85.1 million

Migraine, Sleep Disorder, Encephalitis, and Stroke patients.

1 in 6 Americans are currently affected by brain disease
A globally aging population is increasing the shortage of specialists to conduct and interprete EEGs
Less than 1% of US hospitals are level 4 epilepsy center, with 24/7 EEG coverage
Only 30% of US hospitals have the equipment and on-hand professionals to perform an EEG

Sources: alz.org, cdc.gov, americanbrainfoundation.org

Market Growth

Huge Market Growth Potential

This is an early stage investment with huge growth potential because of its inclusion in multiple markets that are expected to expand rapidly over the next few years:

Medtech Market – Growing at a CAGR of 5% from $176.7 billion in 2020 to $262.4 billion in 2028
Telemedicine Market – Growing at a CAGR of 23.5% from $34.2 billion in 2018 to $185.6 billion in 2026
Brain Scientific’s advanced technology brings EEGs to millions of patients in widely underserved markets
These revolutionary, cost effective, MedTech products will vastly widen the availability of EEGs and bring neurological care to the masses through teleneurology

Source: www.grandviewresearch.com

The growth prospect of this opportunity is as certain
as the fact that the world’s population is getting
older, every single day.

COVID Aftermath

Source: worldometers.info/coronavirus/worldwide-graphs

In the aftermath of COVID-19, doctors all over the world are finding that many of those who contracted coronavirus have acquired long-lasting neurological conditions.

There is no detailed knowledge of what these neurological conditions may be or may mean for the afflicted. EEGs are going to be instrumental in diagnosing and organizing treatment for those afflicted.

Brain Scientific’s revolutionary technological advancements in the world of EEGs are going to be key players in the rapid advancement of neurological discoveries and treatment insights in this area. This represents a huge opportunity for growth the company valuation.

Product Market Fit

In the US a rapidly aging population is creating a shortage of neurologists, and 20 states have fewer than 10 neurologists per 10,000 patients. These areas are called ‘neurology deserts’. Worldwide, there are neurology deserts much larger than those in the US, which leaves a large percentage of world’s population untreated because their neurological afflictions go undiagnosed.

This market is ripe for technological innovation, and publicly traded companies, like Brain Scientific are leading the charge.

Brain Scientifc’s goal is to eradicate these neurology deserts in the USA and make EEGs accessible to everyone
Making EEGs widely available using their proprietary technology Brain Scientific (BRSF) sees a significant increase in its stock price in the future

New Advanced Technology

Brain Scientific’s two patented and FDA approved products, NeuroCap™ and NeuroEEG™ have already disrupted the EEG market and thrust it into 21st century by, reducing size, and incorporating wireless bluetooth technology and secure cloud storage.

Over 80% reduction in setup time

(from 30 minutes to 5 minutes)

Can be fitted by anyone who received minimal training

Patented and FDA approved

Disposable, eliminating the chance of spreading infections

Small and completely portable

Doesn’t require acutely trained technicians or on-hand neurologists

(massive advantage over current systems)

Backwards compatible with existing 3rd party systems

Brain Scientific has commenced development of its market disrupting proposed Brain E-Tattoo device for the brain diagnostics market, utilizing revolutionary, Nobel Prize winning material graphene, which is expected to feature minimally invasive, subcutaneous graphene electrode implants paired with a micro EEG. The proposed Brain E-Tattoo device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders.

Via a graphene based electrode system connected to a micro EEG that is clipped behind the ear, signals are collected by the sensors and wirelessly and securely stored in the cloud, where AI performs continuous analysis.

Both of these technologies are market disruptors. Integration with AI and machine learning will enable faster, more accurate diagnostics, improved predictability of events such as strokes and seizures before they actually happen, and enable a better standard of care.

Brain Scientific is a great opportunity for seasoned industry veterans as well as first time investors.

Stay updated on company news and announcements

The Team

Boris Goldstein

Co-Founder & Executive Chairman

Dr. Boris Goldstein is a visionary pioneer with the intention to revolutionize and democratize the MedTech industry. With over two decatdes of experience in neuro-net informatics, brain image recognition and processing, artificial intelligence and management of robotic systems. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital to develop innovative companies and startups in diverse industries. Built a suite of first-to-market companies as a technology-oriented leader, including RYAH MedTech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. Co-Founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov

Ph.D., Director

Dr. Nickolay V. Kukekov is Senior Partner at BRIC Biotech Ventures LLC, and a Managing Director at Custom Equity Research, Inc. Kukekov previously worked as a senior healthcare investment banker at Rodman & Renshaw. Through his illustrious career, Kukekov has attained a Bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. in Neuroscience from Columbia University, College of Physicians and Surgeons in New York. Along the way, he has picked up several prestigious research scholarship awards and been featured in various peer-review publications.

Amy Griffith

Vice President of Strategy & Business Development

Amy Griffith is a seasoned professional and an innovative sales expert with years of experience in the medical and healthcare industries. She leads the development of strategic and tactical initiatives and new sales strategies for Brain Scientific. Previously, Griffith has held senior positions at technology companies and has worked with numerous start-ups on creating and implementing strategic sales programs. At Glaxosmithkline, she promoted a product portfolio to over 400 psychiatrists, neurologists, internists, OB/GYN, and family practice physicians.

Irina Nazarova

Marketing Director

Irina Nazarova is a media and marketing professional with an extensive journalism background, specializing in Content Strategy, Digital Marketing, and Public Relations. She previously held a CEO role at 7+7 Media, Inc. In 2010-2016, she was a publisher of DOM-2 Magazine and Moscow: Instructions for Use Newspaper. Nazarova graduated from The New School (Media Management) and Moscow State University (Journalism).

In Summary

Brian Scientific (OTC: BRSF) is a top stock pick for 2021, expecting exceptional growth in the very near future. Two patented, FDA approved devices are going to lead the expansion of EEGs and the availability of neurological care through the new, high growth market of teleneurology.

This is an opportunity not to be missed! Brain Scientific will soon be the lead player in the neurology tech space with their revolutionary, 3rd party compatible equipment which will soon be present in every market in the USA.